Intravesical Immunotherapy Shows Recurrence Control in BCG-Unresponsive Papillary-Only Non–Muscle-Invasive Bladder Cancer

1. CG0070 shows 95.7% recurrence-free survival at 3 months. 2. Treatment involves weekly intravesical instillations. 3. Study included 56 patients, predominantly older males. 4. Most adverse events were mild (grade 1 or 2). 5. No patients underwent radical cystectomy during follow-up. 6. Future studies and longer follow-up are needed. 7. FDA submission for CG0070 is in progress.